With almost 70,000 tests performed and follow-up studies for up to ~8+ years, PancraGEN® can help aid gastroenterologists in determining pancreatic cancer risk and help inform patient management.
PancraGEN® is a fully integrated reporting of first-line and molecular test results that improves risk stratification by use of “integrated molecular pathology”, a proprietary and well documented combination assessment of tumor suppressor genes, loss of heterozygosity, imaging, chemistries, and other first-line testing.
Integration of molecular and first-line test results helps physicians in their determination of the best course of action in patient management—from surgery to active surveillance.
